Home ProductsNovel Coronavirus Vaccine

SARS COV 2 Trial Novel Coronavirus Covid 19 Vaccine

SARS COV 2 Trial Novel Coronavirus Covid 19 Vaccine

  • SARS COV 2 Trial Novel Coronavirus Covid 19 Vaccine
SARS COV 2 Trial Novel Coronavirus Covid 19 Vaccine
Product Details:
Place of Origin: CHINA
Brand Name: CoronaVac
Model Number: SARS-CoV-2
Payment & Shipping Terms:
Minimum Order Quantity: 10000
Price: Negotiable
Delivery Time: 20 days
Payment Terms: L/C, T/T
Supply Ability: 200000pcs/day
Contact Now
Detailed Product Description
High Light:

Novel Coronavirus Covid 19 Vaccine

,

Trial coronavirus covid 19 vaccine

,

0.9Version SARS COV 2 Vaccine

COVID-19 Vaccine Trial Novel coronavirus inactivated vaccine

 

Version:0.9 StartHTML:0000000105 EndHTML:0000001798 StartFragment:0000000141 EndFragment:0000001758

Volunteer Subjects: Phase I/II clinical trials in Healthy Adult Aged 18-59
Trial Design: Typical double blinded, randomized, placebo control trial
Schedule/ No.
Volunteers Phase I Phase II Volunteers
0,14 day 72 300
0,28 day 72 300
Total 144 600
Studies on elderlies are being carried on;
Studies on adolescents and pediatric groups are going to commence;

 

 Model: 2 cases (2/2) showed severe interstitial
pneumonia with Vascular and peribranchial
inflammatory cells infiltrate
 Adjuvant: 1 case (1/2) showed mild interstitial
pneumonia; 1 case (1/2) showed Severe
interstitial pneumonia with Vascular and
peribranchial inflammatory cells infiltrate
 High dose group: 4 cases (4/4) showed
mild interstitial pneumonia; Compare with
model group and adjuvant group, the
pulmonary pathological change of
vaccine groups has been siganificantely
reduced.
 Medium dose group: 4 cases (4/4)
showed mild interstitial pneumonia;
Compare with model group and
adjuvant group, the pulmonary
pathological change of vaccine groups
has been siganificantely reduced.

Our History &Products
We focuses on the Research, Development, Manufacture and Commercialization
of vaccines for infectious diseases with significant unmet medical need.
Worldwide Market & Footprint
The cumulative global sales are nearly 160 million doses. In 2019, an average of 112 people per minute were vaccinated with Sinovac’s
vaccines to obtain immune protection.
Sinovac’s vaccine has been sold in 22 countries around the world, has been registered in 17 countries, and is being registered in 26
countries, covering 3.25 billion people 68 million newborns
The hepatitis A vaccine Healive® ® is the first HepA vaccine in China to pass WHO-PQ, and is being exported to more than 10 “Belt and
Road” countries and international organizations such as UNICEF and PAHO. 

 

1. What is a vaccine

Vaccines are autoimmune preparations made from pathogenic microorganisms and their metabolites through artificial attenuation, inactivation, or genetically modified methods to prevent infectious diseases. The vaccine retains the characteristics of pathogenic bacteria that stimulate the animal's immune system. When animals come into contact with this innocuous pathogen, the immune system will produce certain protective substances, such as immune hormones, active physiological substances, special antibodies, etc.; when the animal comes into contact with this pathogen again, the animal’s immunity The system will follow its original memory and create more protective substances to prevent pathogenic bacteria from harming.

 

2. Where is the new crown vaccine injected?

The vaccinated site of the new crown inactivated vaccine is in the deltoid muscle of the upper arm. The immunization program is 2 injections, and the interval between the 2 injections is 14-28 days.

 

3. Adverse reactions of new crown vaccine

After vaccination, some people may experience redness, swelling, induration, pain, etc., and some people will have symptoms such as fever, fatigue, nausea, headache, and muscle aches. The more serious abnormal reaction is anaphylactic shock, but the incidence is very low. . At present, more than 9 million people have been vaccinated in my country, and no serious adverse reactions have occurred.

 

4. People who are not suitable for vaccination

Pregnant and lactating women

Cancer patients and people with severe liver and kidney disease, diabetes, etc.

Acute phase of fever and infection

People with immunodeficiency and immune disorders

 

5. Can the elderly and children be vaccinated?

At present, the scope of vaccination is controlled within the age range of 18-59 years old. People below 18 years old and above 59 years old need to wait for further experimental data before vaccination.

 

6. The duration of antibody after vaccination

Current data show that antibodies can still maintain a high level 6 months after vaccination.

 

7. Can you sit back and relax after being vaccinated?

No, the protective effect of vaccination is not 100%, and it takes time to produce protective antibodies. Therefore, regardless of whether you have been vaccinated or not, you should actively respond to national epidemic prevention measures, insist on wearing masks, washing your hands frequently, avoid going to crowded places, reduce unnecessary outings, and pay attention to your own safety. If symptoms such as fever, cough, fatigue, etc. occur, go to the designated hospital for examination in time and avoid contact with large areas of people.

 

 

SARS COV 2 Trial Novel Coronavirus Covid 19 Vaccine 0

Contact Details
Jiangsu Shengde Import and Export Trade Co., Ltd

Contact Person: shengde

Tel: +8613915839029

Send your inquiry directly to us (0 / 3000)